Results 191 to 200 of about 15,740 (203)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Annals of Oncology, 2018
Christopher Flowers, C Nolan, N Fowler   +2 more
exaly  

Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 Inhibitor

Journal of Clinical Pharmacology, 2016
Silpa Nuthalapati, Kevin Freise, Ahmed Hamed Salem   +2 more
exaly  

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL‐2 Inhibitor: Results of a Single‐ and Multiple‐Dose Study

Journal of Clinical Pharmacology, 2016
Ahmed Hamed Salem, David Chien
exaly  

Venetoclax for the treatment of chronic lymphocytic leukemia

Expert Opinion on Investigational Drugs, 2017
Anna Grazia Recchia, Massimo Gentile, Massimo Martino   +2 more
exaly  

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

Cell Stem Cell, 2020
Clay Smith, Daniel Pollyea, Amanda C Winters   +2 more
exaly  

Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma

Journal of Clinical Pharmacology, 2017
Ahmed Hamed Salem, Rod A Humerickhouse
exaly  

Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects

Clinical Pharmacology in Drug Development, 2018
Ahmed Hamed Salem
exaly  

Venetoclax for the treatment of multiple myeloma

Expert Review of Hematology, 2018
Morie Gertz, Iuliana Vaxman, M Hasib Sidiqi   +2 more
exaly  

Venetoclax

Reactions Weekly, 2017
openaire   +1 more source

Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia

Cell Reports Medicine
Fang Ni
exaly